logo
FDA to review prescription fluoride supplements for kids at risk for tooth decay

FDA to review prescription fluoride supplements for kids at risk for tooth decay

Yahoo23-07-2025
The Trump administration is inching closer to banning fluoride tablets and drops often prescribed to kids who don't have access to fluoridated drinking water and are at high risk for mouths full of decayed teeth.
On Wednesday, the Food and Drug Administration will host a public meeting featuring both supporters and opponents of fluoride supplements. While dentists overwhelmingly say the tablets have been used safely for decades, more than half of the meeting will be spent 'identifying safety concerns and potential risk' associated with the supplements.
A final decision about whether to pull fluoride supplements off the market isn't expected until the end of October. In May, the FDA commissioner, Dr. Marty Makary, announced the agency's intention to get rid of them.
Wednesday's meeting includes 18 speakers, including well-known fluoride skeptics like Dr. Bill Osmonsun, a retired dentist now with the Fluoride Action Network, and Dr. Bruce Lanphear, a professor of health sciences at Simon Fraser University in Canada. Lanphear published a controversial 2019 study suggesting that IQ levels were slightly lower in kids whose mothers had ingested more fluoride while pregnant, research that's frequently cited by Health Secretary Robert F. Kennedy Jr.
Dr. Charlotte Lewis, a professor of pediatrics at the University of Washington School of Medicine, and Dr. Jayanth Kumar, who previously was dental director for California, will counter those presentations.
Dr. James Bekker, a pediatric dentist and a member of the Utah Dental Association who is scheduled to speak at Wednesday's meeting, said: 'Say we take supplements off the market. What's the alternative? There is none.'
Utah and Florida have banned fluoride from public water systems. Similar legislation is under consideration in Kentucky, Massachusetts and Nebraska.
Critics say the risks from fluoride during a child's early years override the benefit of protecting against tooth decay, a disease that can cause pain, infection and other possible health problems.
In an interview with Fox News, Kennedy acknowledged that areas without fluoride in their water are likely to have 'slightly more cavities.'
Bekker was more blunt. 'Buckle up,' he said. 'We're going to have an onslaught of cavities.'
What are fluoride supplements?
Nearly two-thirds of dentists in the United States prescribe fluoride supplements to their patients, especially in areas without community water fluoridation, according to a American Dental Association report this year.
Sodium fluoride tablets and drops are prescription only, and they have been used for decades to prevent tooth decay. A 2011 analysis of 11 studies, including some randomized controlled trials, by French researchers found that 0.25 mg up to 1 mg a day of the supplements reduced rates of cavities in kids by nearly a quarter.
The chewable tablets come in several doses and are particularly important for families who live in areas without fluoride in drinking water and who don't have dental insurance or can't afford regular visits to dentists. Even though Medicaid covers oral health for children, fewer than half went to the dentist at least once a year.
Cavities that erupt in those kids get worse if they're left untreated, and they can cause widespread damage. The decay 'eats away at the bone' around the tooth and sometimes gets into the bloodstream, said Dr. Steven Levy, a professor of preventive and community dentistry at the University of Iowa.
'This is more than just a garden-variety, middle-class person's experience with a cavity,' he said.
Major public health groups, including the American Academy of Pediatrics and the U.S. Preventive Services Task Force, recommend prescribing supplements for children starting at 6 months if the water supply isn't fluoridated.
Fluoride supplements are often given to kids from age 5 until they have their permanent teeth, around age 13 or 14, Bekker said. Babies get drops until they're old enough to chew tablets. They're generally inexpensive.
Over-the-counter vitamins and supplements don't contain fluoride. Fluoride is available over the counter only in toothpaste and mouthwashes.
Limited research on fluoride supplements
According to Makary, the FDA commissioner, ingested fluoride alters the gut microbiome. That assertion appears to hinge on a 2023 review of research on the matter. Scientists in Ireland noted that animal studies suggested ingesting fluoride affected the microbiome but that none of the studies examined fluoride and the human microbiome. They concluded that any possible effect of fluoride on the microbiome is 'still in its early days, and studies investigating the impact of fluoride on the human microbiome have only begun to appear in the literature.'
Makary also objects to the fluoride supplements because they aren't approved by the FDA. Because the supplements had been in use for decades before Congress mandated that drug manufacturers show that their products were not only safe but also effective, they were never required to go through the approval process. For almost as long as the supplements have been prescribed, critics have been concerned about the lack of rigorous data showing their potential health effects and how they protect kids' teeth.
'I think we really need to understand the benefits,' said Linda Birnbaum, a toxicologist and former director of the National Institute of Environmental Health Sciences and the National Toxicology Program. Birnbaum is listed as a speaker at the FDA meeting Wednesday.
Bekker said safety and efficacy of fluoride supplements for kids have long been established.
'Why is this even a question? This is the biggest no-brainer since sliced bread,' he said.
This article was originally published on NBCNews.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

This Air Purifier Is the Cheapest on the Market, You Can Stack Discounts to Get It Nearly Free on Amazon
This Air Purifier Is the Cheapest on the Market, You Can Stack Discounts to Get It Nearly Free on Amazon

Gizmodo

time9 minutes ago

  • Gizmodo

This Air Purifier Is the Cheapest on the Market, You Can Stack Discounts to Get It Nearly Free on Amazon

Living in a city where air pollution seems unavoidable can feel discouraging, but there's something you can do to protect your health right at home: Investing in an air purifier is a simple way to ensure you breathe cleaner air, especially in your bedroom where you spend nearly a third of your life. You don't have to spend $500 on a Dyson to get quality air cleaning – there are more affordable and practical options too. One of these is the Mooka air purifier (B-D02L), available now on Amazon at a record low price of about $39 after stacking discounts (instant discount + promo code), down from $79. See at Amazon The Mooka B-D02L is designed to encompass large rooms, and covers up to 1076 square feet. Since it has a very effective filtration mechanism, it will circulate the air in a 215-square-foot room six times every hour, and perform one full air exchange every hour in larger rooms of up to 1076 square feet. That makes it ideal for a household with pets or children for instance. The H13 True HEPA filter is the heart of this purifier and it is one of the highest efficiencies in particle capture. It traps pollutants down to 0.3 microns, dust (such as pet hair, dust, pollen, smoke, dander) and odors. The system includes a pre-filter and an activated carbon filter that will work together to catch bigger particles and eradicate stinky odors. What's extremely important is that it's also very quiet: Its new brushless motor keeps sound at just 20 decibels which is barely audible. That means you can leave it on while doing work or sleeping without being disturbed. And it draws very little power, so you won't notice your electricity bill. If security is your priority, the purifier also features a child lock to prevent accidental modification by curious kids. Controls on this air purifier are easy to operate: You can have four timer settings (1, 2, 4, or 8 hours) and adjust fan speed via Sleep, Low, Medium, and High. With these controls, you have the power to determine the amount of air you'd like cleaned without wasting energy. There is even a soft night light that will eliminate night stumbling which can be turned off when you want the total blackness of a totally dark room. If you are looking for a budget-friendly solution to clean the air you and your family breathe, this air purifier is a perfect choice. Don't miss that opportunity on Amazon. See at Amazon

OncoX Deepens ABVC Alliance
OncoX Deepens ABVC Alliance

Associated Press

time10 minutes ago

  • Associated Press

OncoX Deepens ABVC Alliance

CEO Yen Wen Pin's IPO Vision Gains Traction as OncoX Expands Pipeline SILICON VALLEY, CA - August 1, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ('Company'), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, today shared a strategic update on its ongoing collaboration with OncoX BioPharma, Inc., a rising oncology player that has licensed four IND-stage drug assets from ABVC. The two companies have taken another step forward, as OncoX continues to unlock funding to support product advancement under its bold, innovation-driven roadmap. Led by its CEO, Mr. Yen Wen Pin, OncoX has leveraged its core competencies in natural product innovation and dietary supplements to build a unique position in oncology. The Company is actively translating its strengths into a pipeline of immunotherapy-driven treatments supported by ABVC's IND-stage programs. Mr. Yen's strategic vision includes building long-term revenue streams through therapeutic innovation and cross-sector expansion. 'We are building OncoX with a long-term vision to deliver real value to patients and investors,' said Mr. Yen Wen Pin, CEO of OncoX BioPharma. 'Through the licensed INDs from ABVC and continued collaboration, we're pushing forward innovative therapies that will anchor our strategy and will help facilitate our momentum, stability, and strong identity in the cancer therapeutics space.' OncoX's platform centers around immunotherapy-inspired cancer treatments derived from ABVC's clinical-stage portfolio. Each program represents a carefully selected opportunity - designed not for the sake of headlines, but for real progress. OncoX has deliberately raised capital in phases, allocating it directly to the development of these candidates. Its recent funding efforts have led to the fulfillment of an additional milestone payment, a sign of both operational discipline and intent. 'We view this partnership as a case study in how smart biotech collaborations can grow over time,' said Dr. Uttam Patil, ABVC's Chief Executive Officer. 'OncoX's consistent execution has translated into steady licensing revenue for ABVC and increasing momentum around these oncology programs. We're optimistic about what the next chapters will bring.' Including this latest milestone, ABVC and its subsidiaries have now recorded a total of $1.396 million in cumulative licensing income from OncoX and other strategic partners, including AiBtl BioPharma and ForSeeCon Eye Corporation. With each step forward, OncoX brings new definition to its roadmap - blending innovation with pragmatism, and aligning business development efforts with the scientific potential of its pipeline. OncoX remains focused on developing not only drug candidates, but a revenue-generating model grounded in credibility and commercial viability. About OncoX BioPharma OncoX BioPharma is a clinical-stage biopharmaceutical company focused on developing next-generation cancer immunotherapies derived from natural sources. The company currently has three proprietary pipeline programs, including its lead product candidate targeting solid tumors and hematologic malignancies, which has demonstrated promising safety and efficacy in early-phase clinical studies and received four INDs (Investigational New Drug Applications) approved by the U.S. FDA. The Company believes that the estimated total market opportunity of its oncology pipeline, inclusive of its existing licensing agreements and assets, is significant. In addition to its therapeutic pipeline, OncoX is actively expanding into cancer-supportive care and preventative health through proprietary natural ingredients. The company has also acquired the Lycogen(R) extraction platform to enter adjacent fields including preventative medicine, chronic disease care (such as benign prostatic hyperplasia, diabetic wound healing), aesthetic medicine, and animal health. These cross-sector applications are projected to reach a global market size of $187 million by 2030, according to Allied Market Research. [1] OncoX operates under a strategic collaboration and manufacturing framework with BioKey Inc., a U.S. FDA-registered facility. The company is expanding its global footprint, with development and commercialization plans in the United States, Japan, Taiwan, and other key Asia-Pacific markets. OncoX is currently preparing for future clinical milestones and pursuing long-term international partnerships to bring its innovative therapies to patients worldwide. [1] About ABVC BioPharma & Its Industry ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus(R)) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company's network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus(R), the Company intends to conduct pivotal clinical trials (Phase III) through global partnerships. Forward-Looking Statements This press release contains 'forward-looking statements.' Such statements may be preceded by the words 'intends,' 'may,' 'will,' 'plans,' 'expects,' 'anticipates,' 'projects,' 'predicts,' 'estimates,' 'aims,' 'believes,' 'hopes,' 'potential,' or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC's website at The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. Contact: Uttam Patil Email: [email protected]

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store